Last reviewed · How we verify
Sapylin
Sapylin, marketed by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, holds a unique position in its therapeutic segment, though specific revenue figures are not disclosed. The drug's key composition patent is set to expire in 2028, providing a clear period of exclusivity and potential market protection. However, the lack of detailed competitive landscape and trial results poses a significant risk, as it may be challenging to assess Sapylin's long-term market sustainability and efficacy against emerging therapies.
At a glance
| Generic name | Sapylin |
|---|---|
| Sponsor | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Sapylin Versus Dexamethasone Inhalation for CCRT-Induced Oral Mucositis in Nasopharyngeal Carcinoma (PHASE3)
- Combination of Stereotactic Radiosurgery and Enhanced Immunotherapy for Recurrent Glioblastomas(inSituVac2)(CSREIG) (PHASE1, PHASE2)
- Contrast The Role of Avitene And OK-432 in Reducing Seroma Formation After Axillary Lymphadenectomy for Breast Cancer (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sapylin CI brief — competitive landscape report
- Sapylin updates RSS · CI watch RSS
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University portfolio CI